Literature DB >> 11463415

Hepatitis and death following vaccination with 17D-204 yellow fever vaccine.

R C Chan, D J Penney, D Little, I W Carter, J A Roberts, W D Rawlinson.   

Abstract

We describe a man vaccinated with the 17D204 strain of yellow fever virus, who subsequently died of yellow fever. Sequencing of the NS5-39 untranslated region showed that the virus isolated from the patient was identical to the vaccine strain of the same batch, and different from wild-type virus. Both viruses contained a mutation, although the association of this mutation with virulence is unknown. Severe, rapidly progressive, and ultimately fatal disease can follow use of the 17D204 vaccine strain. There is need for renewed discussion as to the safety of the vaccine and the indications for its use.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11463415     DOI: 10.1016/S0140-6736(01)05341-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  30 in total

1.  Yellow fever vaccine.

Authors:  Philip P Mortimer
Journal:  BMJ       Date:  2002-02-23

2.  Yellow Fever Immunizations: Indications and Risks.

Authors:  Mary E. Wilson; Lin H. Chen; Elizabeth D. Barnett
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

3.  Molecular characterization of a hamster viscerotropic strain of yellow fever virus.

Authors:  Monica A McArthur; Miguel T Suderman; John-Paul Mutebi; Shu-Yuan Xiao; Alan D T Barrett
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

Review 4.  Recent developments: Travel medicine.

Authors:  Jane N Zuckerman
Journal:  BMJ       Date:  2002-08-03

5.  Mapping the risk of yellow Fever infection.

Authors:  David R Hill
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

6.  A global perspective on vaccine safety and public health: the Global Advisory Committee on Vaccine Safety.

Authors:  Peter I Folb; Ewa Bernatowska; Robert Chen; John Clemens; Alex N O Dodoo; Susan S Ellenberg; C Patrick Farrington; T Jacob John; Paul-Henri Lambert; Noni E Macdonald; Elizabeth Miller; David Salisbury; Heinz-J Schmitt; Claire-Anne Siegrist; Omala Wimalaratne
Journal:  Am J Public Health       Date:  2004-11       Impact factor: 9.308

Review 7.  Incubation periods of mosquito-borne viral infections: a systematic review.

Authors:  Kara E Rudolph; Justin Lessler; Rachael M Moloney; Brittany Kmush; Derek A T Cummings
Journal:  Am J Trop Med Hyg       Date:  2014-03-17       Impact factor: 2.345

8.  Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States.

Authors:  Thomas P Monath
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

9.  Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination.

Authors:  Maria Luiza Silva; Luçandra Ramos Espírito-Santo; Marina Angela Martins; Denise Silveira-Lemos; Vanessa Peruhype-Magalhães; Ricardo Carvalho Caminha; Péricles de Andrade Maranhão-Filho; Maria Auxiliadora-Martins; Reinaldo de Menezes Martins; Ricardo Galler; Marcos da Silva Freire; Rugimar Marcovistz; Akira Homma; Dirk E Teuwen; Silvana Maria Elói-Santos; Mariléia Chaves Andrade; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  Clin Vaccine Immunol       Date:  2009-11-11

10.  Advanced age a risk factor for illness temporally associated with yellow fever vaccination.

Authors:  M Martin; L H Weld; T F Tsai; G T Mootrey; R T Chen; M Niu; M S Cetron
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.